| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | ZIP9; ZIP-9 |
| WB Predicted band size | 32 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human SLC39A9 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SLC39A9抗体的3篇文献示例(注：以下内容为虚构，仅用于示例格式，实际文献需通过数据库查询获取)：
1. **标题**: "SLC39A9 regulates intracellular zinc homeostasis and promotes colorectal cancer progression"
**作者**: Zhang Y, et al. (2020)
**摘要**: 研究通过SLC39A9抗体发现其在结直肠癌中高表达，通过调控锌离子稳态激活下游致癌信号通路，促进肿瘤细胞增殖和迁移。
2. **标题**: "SLC39A9 deficiency impairs macrophage polarization and enhances susceptibility to bacterial infection"
**作者**: Wang L, et al. (2021)
**摘要**: 利用SLC39A9抗体敲除模型，发现该蛋白通过调节巨噬细胞中铁死亡(ferroptosis)相关通路，影响宿主对细菌感染的免疫防御能力。
3. **标题**: "SLC39A9 interacts with mTORC1 to modulate cellular nutrient sensing"
**作者**: Chen X, et al. (2023)
**摘要**: 通过免疫共沉淀(使用SLC39A9抗体)揭示SLC39A9与mTORC1复合物互作，参与细胞对氨基酸摄取的调控，影响代谢疾病发展。
4. **标题**: "A novel SLC39A9 antibody-based biomarker panel for early pancreatic cancer diagnosis"
**作者**: Liu H, et al. (2022)
**摘要**: 开发高特异性SLC39A9抗体，结合临床样本分析，证实其在胰腺癌早期诊断和预后评估中的潜在应用价值。
(注：以上文献为示例，实际研究需查阅PubMed、Google Scholar等平台获取真实数据。)
The SLC39A9 antibody is a research tool designed to detect and study the solute carrier family 39 member 9 (SLC39A9), a zinc transporter protein also known as ZIP9. Belonging to the SLC39/ZIP family, SLC39A9 facilitates cellular zinc uptake from extracellular spaces or intracellular organelles, playing a critical role in maintaining zinc homeostasis. Zinc, an essential micronutrient, is involved in numerous biological processes, including enzymatic activity, immune regulation, and cell signaling. Dysregulation of SLC39A9 has been linked to pathologies such as cancer progression, neurodegenerative disorders, and metabolic diseases, making it a target for mechanistic and therapeutic studies.
SLC39A9 antibodies are typically developed as monoclonal or polyclonal reagents, validated for applications like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), or flow cytometry. These antibodies enable researchers to investigate protein expression levels, subcellular localization (e.g., plasma membrane, endosomes), and tissue-specific distribution. High-quality antibodies are often verified using knockout cell lines or siRNA-mediated silencing to confirm specificity, given the structural similarities among ZIP transporters. However, challenges remain, including potential cross-reactivity with related proteins or variability due to post-translational modifications.
Recent studies highlight SLC39A9's role in cancer metastasis, Alzheimer’s disease, and hormonal signaling, underscoring the antibody's utility in both basic research and translational medicine. Its application extends to exploring zinc's impact on cellular proliferation, apoptosis, and immune responses, offering insights into disease mechanisms and therapeutic targeting.
×
